Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

This study is testing whether combining two drugs — donafenib (a targeted therapy) and envafolimab (an immunotherapy) — after surgery can reduce the chance of liver cancer (hepatocellular carcinoma) coming back in patients who are at high risk for recurrence. **You may be eligible if...** - You are between 18 and 80 years old and had surgery to remove liver cancer, confirmed by pathology, with clear margins - Your tumor has at least one high-risk feature: tumor ≥ 5 cm plus blood vessel invasion, 3 or more tumors, or portal vein involvement (vp1 or vp2) - No signs of cancer recurrence on imaging 3–7 weeks after surgery - Your liver and organ function are adequate **You may NOT be eligible if...** - You already show signs of cancer recurrence after surgery - You have other active cancers - Your liver function or blood counts are significantly impaired - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.